Form 51-102F3
Material Change Report

Item 1 Name and Address of Company

Aim Explorations Ltd. (the "**Company**")
Suite 311-409 Granville Street
Vancouver, British Columbia
V6C 1T2

Item 2 Date of Material Change

March 10, 2014

Item 3 News Release

A news release was issued by the Company on March 10, 2014 and distributed through Stockwatch and filed on SEDAR.

Item 4 Summary of Material Change

The Company is pleased to announce that it has entered into an agreement in principle with Heart Force Medical Inc. ("**HFM**") dated March 10, 2014 (the "**LOI**") pursuant to which AIM will acquire all of the issued and outstanding shares of HFM (the "**HFM Shares**") and all of the issued and outstanding non-interest bearing, unsecured convertible notes (the "**HFM Notes**") of HFM (the "**Proposed Transaction**").

Item 5 Full Description of Material Change

Please see the Company's new release dated March 10, 2014, attached hereto as Schedule A which is also available at www.sedar.com.

Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not Applicable.

Item 7 Omitted Information

Not Applicable.

Item 8 Executive Officer

Geoff Balderson: President, Chief Executive Officer, Chief Financial Officer and Secretary
Telephone: (604) 602-0001

Item 9 Date of Report

March 10, 2014

SCHEDULE "A"

AIM EXPLORATIONS LTD. ANNOUNCES DETAILS OF QUALIFYING TRANSACTION WITH HEART FORCE MEDICAL INC.

March 10, 2014: Vancouver, B.C.: Aim Explorations Ltd. (TSX-V: AXN.P) ("**AIM**" or the "**Company**") is pleased to announce that it has entered into an agreement in principle with Heart Force Medical Inc. ("**HFM**") dated March 10, 2014 (the "**LOI**") pursuant to which AIM will acquire all of the issued and outstanding shares of HFM (the "**HFM Shares**") and all of the issued and outstanding non-interest bearing, unsecured convertible notes (the "**HFM Notes**") of HFM (the "**Proposed Transaction**").

HFM is a private company incorporated in British Columbia that is in the final stages of commercializing its first product (the "**SCG**"), a non-invasive system that assesses the electro-mechanical function of the heart. The system consists of a base station and a sensor that is placed on the skin at the lower end of the sternum to non-invasively sense the seismic forces generated by the beating heart, quickly and inexpensively.

The system displays a seismocardiograph waveform that measures the systolic timing intervals as well as the relative force of cardiac contractility. This information is useful for a variety of medical applications including: assessing patients for the early signs of cardiac disease or asymptomatic heart disease; monitoring patients during surgery under general anesthesia; programming dual-chamber pacemakers; fitness evaluation and potentially to assess the effectiveness of treatments for cardiac ailments.

Currently, physicians can only assess the heart's electro-mechanical function by using invasive, time-consuming and expensive catheters or echocardiography HFM has spent approximately seven years and over $10 million developing and clinically testing the device. HFM has won an award for innovation, received Canadian government recognition in the form of grants and was granted FDA 510K clearance in the United States on a predecessor device. The current product improves on the previous device that required manual data analysis by incorporating automatic waveform annotation, analysis and display as part of an integrated system.

The SCG is a Class II medical device, which requires regulatory approval before marketing can begin. Final development and testing has been completed and HFM is in the process of selecting a Canadian company to manufacture the device. Marketing trials are scheduled to commence this year and the Company is undertaking the necessary steps to obtain Health Canada approval.

Transaction Terms

The Proposed Transaction will constitute AIM's Qualifying Transaction as such term is defined in the policies of the TSX Venture Exchange (the "**Exchange**"). The Proposed Transaction is an arm's length transaction and will be subject to a number of conditions, including but not limited to, Exchange acceptance and all other necessary approvals.

Pursuant to the terms of the LOI, at the closing of the Proposed Transaction the HFM Shares will be exchanged for common shares in the capital of AIM (the "**AIM Shares**") on a one-for-one basis and the HFM Notes will be exchanged for AIM Shares on the basis of one AIM share for each $0.10 of outstanding principal amount of HFM Notes. As a result, HFM will become a wholly-owned subsidiary of AIM. HFM currently has 37,320,539 common shares issued and outstanding.

Prior to the closing of the Proposed Transaction, HFM will undertake a financing (the "**Bridge Financing**") of HFM Notes to raise gross proceeds of approximately $750,000 to fund its operations and transaction costs to closing. The HFM Notes will mature 18 months after issuance and will be convertible by the holder at any time into HFM Shares at a price of $0.10 per HFM Share. The HFM Notes will be automatically converted into or exchanged for AIM Shares at the closing of the Proposed Transaction as described above.

Concurrent with the closing of the Proposed Transaction, AIM will undertake a private placement of AIM Shares (the "**Private Placement**") at a price of $0.25 per share (or such other price as may be agreed upon by AIM and HFM) for gross proceeds of not less than $2,000,000.

AIM will also issue 200,000 AIM Shares as a finder's fee to an arm's length party upon closing of the Proposed Transaction.

The LOI will be replaced by a definitive agreement (the "**Definitive Agreement**") that incorporates the terms of the LOI together with the representations, warranties, covenants, conditions, indemnifications and agreements customary for transactions such as the Proposed Transaction. It is anticipated that the transaction will be structured as a plan of arrangement under the *Business Corporations Act* (British Columbia).

The Proposed Transaction is subject to fulfillment or waiver of certain closing conditions including:

- completion of the Bridge Financing by April 30, 2014;
- HFM and AIM obtaining all required court, Exchange, regulatory, shareholder and third party approvals and consents;
- completion of the Private Placement;
- negotiation and execution of the Definitive Agreement;
- receipt by HFM of a favourable fairness opinion addressed to it in respect of the Proposed Transaction; and
- other customary conditions to closing as set forth in the Definitive Agreement, such as compliance with each party's covenants and accuracy of representations and warranties.

The table below sets forth certain selected financial information for HFM for its last two completed fiscal years expressed in Canadian dollars. HFM expensed all research and development expenses, net of tax credits received, as incurred.

Balance Sheet	As at December 31, 2013 (unaudited)	As at December 31, 2012 (audited)
Total Assets	$ 283,242	$ 829,522
Total Liabilities	$ 148,699	$ 156,092
Income Statement	For the year ended December 31, 2013 (unaudited)	For the year ended December 31, 2012 (audited)
Revenue	$ -	$ -
Operating and Development Expenses	$ 538,884	$ 1,119,029
Net Loss	$ (538,884)	$ (1,119,029)

The Resulting Issuer

Upon completion of the Proposed Transaction, AIM (the "**Resulting Issuer**") expects to be a Tier 2 Technology or Life Sciences Issuer and to change its name to "Heart Force Medical Corp." or such other name that is acceptable to the Exchange and applicable regulatory authorities.

The Resulting Issuer will grant an additional 4,000,000 stock options with an exercise price equal to the price of the AIM Shares issued under the Private Placement. Existing AIM options held by persons no longer involved with the Resulting Issuer will expire 12 months following closing of the Proposed Transaction.

Board of Directors and Management of the Resulting Issuer

On closing of the Proposed Transaction, the Resulting Issuer's board will be restructured to be comprised of no more than five individuals, including Geoff Houlton, Bill McCartney and Bruno Maruzzo. Dr. Houlton will be also be appointed as President and Chief Executive Officer of the Resulting Issuer. HFM will appoint an additional director to the board of the Resulting Issuer, with the fifth position to be mutually agreed upon by AIM and HFM.

HFM will also appoint a Chief Financial Officer and Corporate Secretary. It is also contemplated that the Resulting Issuer will establish an advisory board of up to five individuals to include industry and capital market participants.

The following is a brief summary of the proposed insiders of the Resulting Issuer:

Geoff Houlton – President and Chief Executive Officer and Director

Dr. Houlton qualified in medicine in Scotland in 1977. In 1983, after residency training in anesthesiology, he joined the UK pharmaceutical industry. In 1987, he became Vice-President of Medical Affairs for Glaxo Canada Inc. and managed all aspects of its local pharmaceutical product development programs. In 1989, the challenges of product and business development lead him to join MDS Health Ventures Ltd. In 1997 he was a founder of BioCatalyst Yorkton Inc., a venture management company, with Yorkton Securities. Between 2005 and 2008 Dr. Houlton served as a health sciences analyst for Canadian investment banks. In late 2008, Dr. Houlton was appointed President and Chief Executive Officer of HFM.

Bill McCartney – Director

Mr. McCartney received a B. A. from Simon Fraser University in 1978 and has been a member of the Institute of Chartered Accountants of British Columbia since 1980. Since 1990 Mr. McCartney has been the President of Pemcorp Management Inc., a private company which provides corporate finance and administrative management services to private and public companies. He is a former founding partner of Davidson & Company, Chartered Accountants. He is a currently a member of the local (policy) advisory committee to the Toronto Stock Exchange and TSX Venture Exchange.

Mr. McCartney is or has been a founder, director or officer of a number of public companies including, Mercer International Inc. (TSX, NASDAQ: MRI), Terrace Energy Corp. (TSXV: TZR), Dynasty Metals & Mining Inc. (TSX: DMM), Exeter Resource Corp. (TSX, AMEX: XRC), Sunward Resources Ltd. (TSX: SWD) and Newstrike Capital Inc. (TSXV: NES).

Bruno Maruzzo – Director
Mr. Maruzzo holds a BASc in Electrical Engineering from the University of Waterloo, an MASC in Biomedical Engineering from the University of Toronto and an MBA from the University of Toronto. He has over 20 years of experience in working with small to medium size private and public technology companies in the computer, electronics and biotechnology fields as well as working in venture capital investing in technology oriented companies.

Mr. Maruzzo has been involved with a number of public companies including Pinetree Capital Ltd. (TSX: PNP), Critical Outcome Technologies Inc. (TSXV: COT), Diagnos Inc. (TSXV: ADK), Sintana Energy Inc. (TSXV: SNN) and Hamilton Thorne Limited (TSXV: HTL).

Sponsorship

Sponsorship of a qualifying transaction of a capital pool company is required by the Exchange unless exempt in accordance with Exchange Policies. AIM may apply for an exemption from sponsorship requirements; however there is no assurance that it will obtain this exemption.

ABOUT AIM

Additional information will be disclosed in subsequent news releases prior to the resumption of trading. Trading of
the common shares of AIM has been halted in connection with the dissemination of this news release, and is expected to remain halted until completion of the Proposed Transaction.

For further information contact:
Geoff Balderson
President, Chief Executive Officer, Chief Financial Officer and Secretary
Telephone: 604.602.0001
Fax: 604.488.0886
Email: gbalderson@telus.net

Completion of the Proposed Transaction is subject to a number of conditions, including but not limited to, Exchange acceptance and if applicable pursuant to Exchange requirements, majority of the minority shareholder approval. Where applicable, the Proposed Transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the Proposed Transaction will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the Proposed Transaction, any information released or received with respect to the Proposed Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative. The Exchange has in no way passed upon the merits of the Proposed Transaction and has neither approved nor disapproved the contents of this press release.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release contains forward-looking statements about HFM. Forward-looking statements are statements that are not historical facts. The forward-looking statements in this press release are subject to various risks, uncertainties and other factors that could cause the Resulting Issuer's actual results or achievements to differ materially from those expressed in or implied by forward-looking statements. These risks, uncertainties and other factors include, without limitation, the ability of HFM and AIM to complete the Bridge Financing and Private Placement, HFM and AIM obtaining all required court, Exchange, regulatory, shareholder and third party approvals and consents, the ability of HFM and AIM to negotiate and execute the Definitive Agreement, the uncertainty as to the Resulting Issuer's ability to achieve the goals and satisfy the assumptions of management, general economic factors and other factors that may be beyond the control of the parties. Forward-looking statements are based on the beliefs, opinions and expectations of the management of AIM at the time they are made, and AIM does not ssume any obligation to update its forward-looking statements if those beliefs, opinions or expectations, or other circumstances, should change.